Patents by Inventor Janine Bilsborough

Janine Bilsborough has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD TREATING NEURONAL TISSUE INFLAMMATION USING AN IL-31RA MONOCLONAL ANTIBODY
    Publication number: 20160222123
    Abstract: Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.
    Type: Application
    Filed: April 15, 2016
    Publication date: August 4, 2016
    Inventors: Yue Yao, Janine Bilsborough
  • USE OF AN IL-31 MONOCLONAL ANTIBODY FOR ANTAGONIZING SIGNAL TRANSDUCTION IN SPINAL CORD CELLS
    Publication number: 20160222103
    Abstract: Use of antagonists to IL-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.
    Type: Application
    Filed: April 15, 2016
    Publication date: August 4, 2016
    Inventors: Yue Yao, Janine Bilsborough
  • Methods of antagonizing signal transduction in spinal cord cells using an IL-31Ra or OSMR-b antagonist
    Patent number: 9334322
    Abstract: Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.
    Type: Grant
    Filed: January 27, 2015
    Date of Patent: May 10, 2016
    Assignee: ZymoGenetics, Inc.
    Inventors: Yue Yao, Janine Bilsborough
  • Methods of treating neuronal inflammation using an IL-31 monoclonal antibody
    Patent number: 9334321
    Abstract: Use of antagonists to IL-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.
    Type: Grant
    Filed: January 23, 2015
    Date of Patent: May 10, 2016
    Assignee: ZymoGenetics, Inc.
    Inventors: Yue Yao, Janine Bilsborough
  • DISTINCT EFFECTS OF IFN-GAMMA AND IL-17 ON TL1A MODULATED INFLAMMATION AND FIBROSIS
    Publication number: 20160096885
    Abstract: Described herein are methods and compositions related to Inflammatory Bowel Disease. Specifically TL1A drives regional intestinal inflammation and fibrosis and is differentially modulated by IFN gamma and IL-17a. In one embodiment, the present invention is a method of diagnosing a condition in a subject by determining the presence or absence of IFN gamma and/or IL-17 and diagnosing the subject.
    Type: Application
    Filed: May 16, 2014
    Publication date: April 7, 2016
    Applicant: Cedars-Sinal Medical Center
    Inventors: David Q. Shih, Stephan R. Targan, Janine Bilsborough
  • MITIGATION AND REVERSAL OF FIBROSIS AND INFLAMMATION BY INHIBITION OF TL1A FUNCTION AND RELATED SIGNALING PATHWAYS
    Publication number: 20160060335
    Abstract: The invention relates to methods of treating fibrosis and inflammatory bowel disease. In one embodiment, the present invention treats gut inflammation by administering a therapeutically effective dosage of TL1A inhibitors and/or DR3 inhibitors to an individual. In another embodiment, the present invention provides a method of reversing tissue fibrosis in an individual by inhibiting TL1A-DR3 signaling function.
    Type: Application
    Filed: March 27, 2014
    Publication date: March 3, 2016
    Applicant: Cedars-Sinai Medical Center
    Inventors: David Q. Shih, Stephan R. Targan, Dalin Li, Janine Bilsborough
  • IL-31 MONOCLONAL ANTIBODIES
    Publication number: 20150368336
    Abstract: The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by administering IL-31 monoclonal antibodies. The invention further provides the hybridomas that generate the monoclonal antibodies.
    Type: Application
    Filed: September 2, 2015
    Publication date: December 24, 2015
    Inventors: Anthony W. Siadak, Janine Bilsborough, Shirley Rene
  • Polynucleotides encoding IL-31 monoclonal antibodies
    Patent number: 9156909
    Abstract: The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by administering IL-31 monoclonal antibodies. The invention further provides the hybridomas that generate the monoclonal antibodies.
    Type: Grant
    Filed: September 19, 2013
    Date of Patent: October 13, 2015
    Assignee: ZymoGenetics, Inc.
    Inventors: Anthony W. Siadak, Janine Bilsborough, Shirley Rene
  • Methods of treatment using IL-31RA
    Patent number: 9139651
    Abstract: The present invention relates to methods of treating patients suffering from Contact dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia aereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination by administering an IL-31RA antagonist.
    Type: Grant
    Filed: January 7, 2011
    Date of Patent: September 22, 2015
    Assignee: ZymoGenetics, Inc.
    Inventor: Janine Bilsborough
  • METHODS OF ANTAGONIZING SIGNAL TRANSDUCTION IN SPINAL CORD CELLS USING AN IL-31RA OR OSMR-B ANTAGONIST
    Publication number: 20150132300
    Abstract: Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.
    Type: Application
    Filed: January 27, 2015
    Publication date: May 14, 2015
    Inventors: Yue Yao, Janine Bilsborough
  • METHODS OF TREATING NEURONAL INFLAMMATION USING AN IL-31 MONOCLONAL ANTIBODY
    Publication number: 20150132299
    Abstract: Use of antagonists to IL-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.
    Type: Application
    Filed: January 23, 2015
    Publication date: May 14, 2015
    Inventors: Yue Yao, Janine Bilsborough
  • Methods of treating pain using an IL-31Ra or OSMR-b antagonist
    Patent number: 8974783
    Abstract: Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.
    Type: Grant
    Filed: February 7, 2014
    Date of Patent: March 10, 2015
    Assignee: ZymoGenetics, Inc.
    Inventors: Yue Yao, Janine Bilsborough
  • Methods of treating pain using an IL-31 monoclonal antibody
    Patent number: 8968732
    Abstract: Use of antagonists to IL-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: March 3, 2015
    Assignee: ZymoGenetics, Inc.
    Inventors: Yue Yao, Janine Bilsborough
  • Methods of using IL-31 antagonists in diseases mediated by cutaneous lymphocyte antigen positive T cells
    Patent number: 8926957
    Abstract: The present invention relates to predicting therapeutic response of treating patients suffering from itching and pruritis mediated by cutaneous lymphocyte antigen positive T cells in atopic dermatitis. The invention also includes methods of predicting a therapeutically responsive patient population.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: January 6, 2015
    Assignee: ZymoGenetics, Inc.
    Inventors: Janine Bilsborough, Jane A. Gross
  • METHODS OF TREATING PAIN USING AN IL-31RA OR OSMR-B ANTAGONIST
    Publication number: 20140186346
    Abstract: Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.
    Type: Application
    Filed: February 7, 2014
    Publication date: July 3, 2014
    Applicant: ZymoGenetics, Inc.
    Inventors: Yue YAO, Janine Bilsborough
  • METHODS OF TREATING PAIN USING AN IL-31 MONOCLONAL ANTIBODY
    Publication number: 20140127206
    Abstract: Use of antagonists to IL-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.
    Type: Application
    Filed: December 19, 2013
    Publication date: May 8, 2014
    Applicant: ZYMOGENETICS, INC.
    Inventors: YUE YAO, JANINE BILSBOROUGH
  • Methods of antagonizing signal transduction in dorsal root ganglion cells
    Patent number: 8685395
    Abstract: Use of antagonists to IL-31Ra and OSMRb are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include soluble receptors, antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.
    Type: Grant
    Filed: March 7, 2013
    Date of Patent: April 1, 2014
    Assignee: ZymoGenetics, Inc.
    Inventors: Yue Yao, Janine Bilsborough
  • POLYNUCLEOTIDES ENCODING IL-31 MONOCLONAL ANTIBODIES
    Publication number: 20140080181
    Abstract: The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by administering IL-31 monoclonal antibodies. The invention further provides the hybridomas that generate the monoclonal antibodies.
    Type: Application
    Filed: September 19, 2013
    Publication date: March 20, 2014
    Applicant: ZymoGenetics, Inc.
    Inventors: Anthony W. Siadak, Janine Bilsborough, Shirley Rene
  • Methods of antagonizing signal transduction in dorsal root ganglion cells
    Patent number: 8637015
    Abstract: Use of antagonists to IL-31 are used to treat inflammation and pain by inhibiting, preventing, reducing, minimizing, limiting or minimizing stimulation in neuronal tissues. Such antagonists include antibodies and fragments, derivative, or variants thereof. Symptoms such as pain, tingle, sensitization, tickle associated with neuropathies are ameliorated.
    Type: Grant
    Filed: January 23, 2013
    Date of Patent: January 28, 2014
    Assignee: ZymoGenetics, Inc.
    Inventors: Yue Yao, Janine Bilsborough
  • Method of reducing pruritis using IL-31 monoclonal antibodies
    Patent number: 8568723
    Abstract: The present invention relates to methods of treating pruritic diseases, including but not limited to Contact dermatitis, Atopic Dermatitis, Drug induced delayed type cutaneous allergic reactions, Toxic epidermal necrolysis, Cutaneous T cell Lymphoma, Bullous pemphigoid, Alopecia wereata, Vitiligo, Acne Rosacea, Prurigo nodularis, Scleroderma, Herpes simplex virus, or combination thereof by administering IL-31 monoclonal antibodies. The invention further provides the hybridomas that generate the monoclonal antibodies.
    Type: Grant
    Filed: July 18, 2011
    Date of Patent: October 29, 2013
    Assignee: ZymoGenetics, Inc.
    Inventors: Anthony W. Siadak, Janine Bilsborough, Shirley Rene